RTI Surgical Inc. (RTI)
(Nasdaq:RTIX), a global surgical implant company, is pleased to announce the first implantation of the company’s map3™ Cellular Allogeneic Bone Graft implant in a foot and ankle procedure.
Dr. Michael Lyons, DPM, an associate member of the American College of Foot and Ankle Surgeons, performed the implantation during a medial column fusion procedure in Indiana. He used the implant’s chips allograft configuration, one of two configurations that will be available.
“Taking into account the published MAPC™ research, I decided to use map3 in a complex case with an immune-compromised patient because it would support the patient’s ability to heal,” said Dr. Lyons. “I was impressed by the ease of use – it required very little time to prepare with simple instructions for preparation. I will definitely use map3 again when it’s appropriate for the patient’s case.”
Map3 cellular allogeneic bone graft is a natural and safe alternative to autograft. Map3 provides a streamlined approach to bone grafting and supplies the three elements necessary for bone repair—osteogenesis, osteoinduction and osteoconduction — in a single allograft. Map3 incorporates multipotent adult progenitor cell-based (MAPC-based) technology with stem cells isolated from the same donor as the other bone material. The MAPC technology, licensed from Athersys, Inc. for this orthopedic application, represents a distinctive type of stem cell with recognized angiogenic and immuno-modulatory properties. Map3 will be available in multiple configurations and sizes, providing bone grafting options for various bone repair, reconstruction and fusion procedures.
“Dr. Lyons’ successful use of map3 in a foot and ankle procedure is an exciting new development following its use in spine procedures,” said Brian K. Hutchison, RTI president and CEO. “The MAPC-based technology offers the greatest potential to create high quality, innovative implants for our surgeons and their patients and will greatly enhance our company’s orthobiologics offerings. We anticipate a limited market release of the implant later this year.”